Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:approves |
gptkb:FDA
EMA WHO |
| gptkbp:availability |
free in many countries
|
| gptkbp:clinicalTrials |
Phase 3 trials completed
emergency use authorization granted |
| gptkbp:controversy |
misinformation
vaccine_hesitancy |
| gptkbp:developedBy |
gptkb:AstraZeneca
gptkb:Johnson_&_Johnson gptkb:Pfizer gptkb:Moderna |
| gptkbp:dosageForm |
one dose for Johnson & Johnson
two doses for Moderna two doses for Pfizer |
| gptkbp:evaluates |
approximately 76% for Johnson & Johnson
approximately 94% for Moderna approximately 95% for Pfizer |
| gptkbp:firstAwarded |
December 2020
|
| gptkbp:geographicalFeature |
over 10 billion doses administered
|
| gptkbp:historicalResearch |
new formulations for variants
combination vaccines with flu |
| https://www.w3.org/2000/01/rdf-schema#label |
COVID-19 vaccine
|
| gptkbp:impact |
reduced hospitalizations
reduced deaths increased immunity |
| gptkbp:manufacturer |
gptkb:Johnson_&_Johnson
gptkb:Moderna,_Inc. gptkb:Sinopharm gptkb:AstraZeneca_PLC gptkb:Sinovac_Biotech gptkb:Novavax gptkb:Pfizer-BioNTech Sputnik V |
| gptkbp:publicAccess |
part of vaccination campaigns
protests against mandates widespread uptake in many regions |
| gptkbp:raisesAwarenessAbout |
after 6 months
|
| gptkbp:research |
ongoing studies on long-term effects
variant effectiveness studies |
| gptkbp:sideEffect |
fatigue
headache muscle pain fever chills |
| gptkbp:storage |
requires cold storage
|
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:type |
mRNA vaccine
inactivated virus vaccine viral vector vaccine |